Thursday 16 October, 2025
Introduction: Up to 70% of non-small cell lung cancer (NSCLC) patients develop brain metastases (BM) during the course of their…
Read morePoster: Drug/Disease Modelling - Oncology
Model informed drug development and CAR-T cells : A review of their use and credibility assessment in the context of EMA centralized procedures
Thursday 16 October, 2025
Introduction/Objectives: Chimeric antigen receptor-engineered T-cells (CAR-T) are a type of modified T-cell that utilises synthetic receptors with monoclonal antibody specificity…
Read moreModel-Based Analysis of RO7589831 Mechanisms of Action in a MSI Cell Line
Thursday 16 October, 2025
Introduction/Objectives: Werner (WRN) helicase is a synthetic lethal target in microsatellite instable (MSI) cancer cells. WRN helicase depletion induces apoptosis…
Read moreExpediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients.
Thursday 16 October, 2025
Introduction: Quizartinib is a highly potent type II FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor. The Phase 3 QuANTUM-First trial…
Read moreAn in vitro to in vivo translational framework for the prediction of drug efficacy in preclinical cell line derived xenografts
Thursday 16 October, 2025
Objectives: Cell line derived xenograft (CDX) mouse models, established by engrafting commercial cell lines into an immunodeficient mouse model, are…
Read moreA Physiologically Based Pharmacokinetic Model for Osimertinib in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III
Thursday 16 October, 2025
Introduction Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is a standard of care for first-line treatment in advanced EGFR-mutated non-small…
Read moreTime-to-event analysis of iron homeostasis to inform survival in cancer patients
Thursday 16 October, 2025
Introduction: Iron is a crucial component required for a variety of vital physiological processes, such as DNA synthesis and energy…
Read moreTranslational modeling of Tumor Growth Inhibition of an antibody-drug conjugate in Oncology
Thursday 16 October, 2025
Objectives: An antibody-drug conjugate (ADC) is under development for the treatment of cancer. Pharmacokinetic (PK) and tumor growth inhibition (TGI)…
Read moreTranslational Modeling of ADC Efficacy and Hematological Toxicity: A QSP Approach for FIH Dose Recommendation with T-DM1 as an Exemplar
Thursday 16 October, 2025
Title: Translational Modeling of ADC Efficacy and Hematological Toxicity: A QSP Approach for FIH Dose Recommendation with T-DM1 as an…
Read moreModel-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization
Thursday 16 October, 2025
Background Combining drugs at optimal dosing regimens remains vital for improving treatment options for patients in oncology. Here we share…
Read more